Background
==========

Intraoperative radiation therapy (IORT) constitutes delivery of radiation to the tumour/tumour bed while the area is exposed during surgery. IORT is capable of delivering high doses of radiation, precisely to the tumour bed with minimal exposure to the surrounding healthy tissues.

Abe *et al.* from the University of Kyoto, Japan, were the first to introduce IORT in the early 1960s reporting its use in various intra-abdominal tumours \[[@ref1]--[@ref3]\].

IORT is typically used in combination with other modalities like maximal surgical resection, external beam radiotherapy (EBRT) or chemotherapy as a part of the multidisciplinary approach.

Efficacy of IORT has been reported in a wide variety of sites like locally advanced and recurrent rectal cancer, retroperitoneal sarcoma, pancreatic cancer, early breast cancer, and selected gynaecologic and genitourinary malignancies.

Rationale for the use of IORT
=============================

Traditionally, surgery is followed by EBRT in most solid tumours for the elimination of any microscopic residual disease and reducing the risk of local recurrence. However, EBRT in the post-operative setting has the following drawbacks:

-   The usual delay between the surgical removal of the tumour and EBRT may allow repopulation of the tumour cells.

-   Difficulty in tumour bed localisation or use of larger margins, which may increase normal tissue morbidity.

Most solid tumours exhibit a dose--response relationship, the likelihood of local control improving with increasing dose; however, there are limitations to the doses that can be delivered even with conformal EBRT techniques due to the presence of dose-limiting structures adjacent to the tumour/tumour bed. Especially, in the setting of gross residual disease, doses with EBRT may never be sufficient to achieve adequate local control without causing significant morbidity.

IORT allows
-----------

-   Precise localisation of the tumour bed and targeted delivery of high-dose radiation to the tumour bed.

-   Minimal exposure of the dose-limiting normal tissues that are displaced away from the tumour bed and shielded from radiation.

-   Opportunities for dose escalation beyond that which can be achieved with EBRT.

-   Opportunities for re-irradiation especially in recurrent cancers where further irradiation with EBRT may not be possible.

Thus, IORT can deliver higher total effective dose to the tumour bed, facilitate dose escalation without significantly increasing normal tissue complications and improve therapeutic ratio compared with EBRT.

IORT may be used alone or in combination with conventionally fractionated EBRT. Most centres use it in combination with EBRT, as it seems to provide the best therapeutic ratio (decreased risk of late normal tissue damage due to the use of fractionation for some part of the dose).

Methods of IORT
===============

Several methods have been used to deliver IORT. Electron beams (electron IORT/IOERT), X-rays (kV IORT) and High-dose-rate brachytherapy (HDR IORT) are some of the commonly used methods for the delivery of IORT in current clinical practice.

Electron IORT
-------------

Introduction of electron IORT (IOERT) marked the beginning of the IORT era in the early 1960s \[[@ref3], [@ref4]\]. Using variable electron energies depth dose distribution could be controlled to provide uniform dose to target area. However, patients needed to be transported from the operating room (O.R) to the radiation department during surgery, posing logistical issues related to transportation and sterilisation \[[@ref2], [@ref5]\]. These problems were overcome with the use of dedicated IOERT facilities, which were quite expensive because of added costs of shielding the O.R and dedicated linear accelerator requirements, limiting their use to few centres in the United States and Europe. The advent of miniaturised, self-shielded, mobile linear accelerators \[[@ref6]\] (Novac7, Hitesys SPA, Aprillia, Italy; 7--10 MeV and the Mobetron, IntraOp Medical Corporation, Sunnyvale, CA, USA; 4--12 MeV) in the 1990s, has brought about resurgence of IORT and allowed its use in many centres across the world while reducing the costs. Greater depth of penetration and dose homogeneity relative to HDR-IORT or kV IORT is possible with these devices. They come with applicators of different shapes and sizes, for the treatment of various sites and can deliver the treatment in a matter of minutes \[[@ref7]\]. However, these applicators are rigid, thus challenging to use in difficult sites (pelvis and narrow cavities) and can treat a maximum diameter of 15 cm only, larger volumes requiring multiple, closely placed fields. Abutment of fields to treat a wider area is made possible by the use of rectangular applicators or D-shaped applicators called 'Squircle'.

HDR IORT
--------

HDR brachytherapy offers distinct dosimetric advantages due to its steep dose fall off and has the ability to deliver high doses to the tumour bed while reducing doses to nearby critical structures, these characteristics of HDR brachytherapy make it well suited for the purpose of IORT. Since many centres already own a HDR after loading machine, which can be transported to the OR for IORT, it reduces the cost of dedicated system; however, like IOERT, a shielded O.R or a shielded room in the O.R complex becomes necessary for HDR IORT. HDR IORT in most centres is delivered using surface applicators like Harrison--Anderson--Mick (HAM) applicator \[[@ref8], [@ref9]\] or superflab \[[@ref10], [@ref11]\] applicators and prescribed at 0.5--1 cm depth. These applicators are flexible, can treat relatively uneven surfaces and come in larger sizes for larger surfaces. Disadvantages of HDR IORT are reduced depth of penetration and prolonged treatment time relative to IOERT.

KV IORT
-------

With increasing use of IOERT in the 1980s, orthovoltage X-rays were attempted for use in IORT to reduce the shielding costs of the OR. However, poor uniformity, higher bone doses and prolonged treatment time quickly reduced the interest in their use. Recently, low-kV (20--50 kV) mobile IORT devices like Intrabeam, (Carl Zeiss AG, Germany) and Axxent Electronic Brachytherapy System (Xoft Inc., Fremont, California) are gaining popularity for use in IORT. They have steep dose gradients and do not require special shielding requirements. They come with spherical applicators and have a very limited depth of penetration of 0.5--1 cm. They are therefore best suited for spherically shaped target volumes as in breast cancer.

With a strong oncological rationale at its heart, IORT in its various forms has been tested throughout the evolution of radiotherapy and has weathered the tests of time and technology showing periodic resurgences with the advent of newer technology. The following section will focus on recently published results to describe the current role of IORT across various sites.

Search strategy and selection criteria
--------------------------------------

A literature search was performed through the PubMed database by using the following terms: 'intraoperative radiotherapy/IORT', 'head and neck cancer', 'breast cancer', 'colorectal/rectal/colon cancers', 'pancreas/pancreatic cancers', 'gastric/stomach cancer', 'soft-tissue sarcoma/sarcoma', 'paediatric/childhood cancers', 'gynaecological cancer', 'uterine/endometrial cancer', 'cervical/cervix cancer', 'renal/kidney cancer', "bladder cancer", and "prostate cancer". IORT was defined as single large dose delivered intraoperatively during surgery, articles of perioperative brachytherapy with continuous low-dose rate or pulsed dose rate or HDR with multiple small fractions, delivered over subsequent days post-surgery were not included in this review. Search was limited to articles published between 1995 and 2017. Reviews, case reports and data presented, only as an abstract at conferences were excluded. Whenever updated data from the same institute was available, earlier articles with smaller numbers were not included. For the purpose of uniformity, in the respective sections, reports combining the results of primary with recurrent colorectal cancers, extremity sarcomas with retroperitoneal sarcomas and metastatic pancreatic cancers with locally advanced pancreatic cancers together were not included in the review. A total of 123 articles were finally included in the review.

Clinical results with IORT
==========================

Head and neck cancers
---------------------

Despite the use of multidisciplinary treatment protocols locoregional recurrences occur in more than 30% of locoregionally advanced head and neck cancers \[[@ref12]--[@ref15]\]. Outcomes are poor even after surgical salvage with high rates of local failure. Re-irradiation, in this setting, has shown to improve local control \[[@ref16]\]. However, persistent late sequelae from previous course of radiotherapy (RT) may hamper the chances of effective re-irradiation with EBRT. IORT is an attractive tool in this setting.

Many retrospective series \[[@ref17]--[@ref22]\] have demonstrated the efficacy of IORT in recurrent head and neck cancer after gross total resection ([Table 1](#table1){ref-type="table"}). Both IOERT and HDR IORT have been used to deliver IORT in recurrent head and neck cancer. Patients selected for IORT mainly consisted of recurrent or persistent cancers, who have been previously irradiated and delivery of sufficient doses of EBRT was not possible at the time of recurrence. Most studies have shown effective local control with acceptable complications \[[@ref17], [@ref19]--[@ref22]\]. Resection status at salvage was the most important factor determining local control \[[@ref17], [@ref19], [@ref21]\]. Microscopically residual tumours did better with IORT \[[@ref23]\], gross residual disease however did not \[[@ref20], [@ref23]\]. Adjuvant EBRT after IORT appears to further improve local control, however the small sample size of these studies precludes any definite conclusions \[[@ref20], [@ref23]\]. Wound complications, osteoradionecrosis (ORN), fistulae, and neuropathy are the most common complications \[[@ref17]--[@ref22]\] after IOERT; however, these are rare with doses less than 20 Gy \[[@ref22]\] and no different than that of re-irradiation with EBRT \[[@ref16]\]. Carotid artery blow out is a rare but a fatal complication that may occur after IORT. Attempts should be made whenever possible to shield or space out the major vessels and nerves from the treatment field.

Breast cancer
-------------

The majority of breast cancer recurrences after breast conservation surgery and whole breast irradiation (WBI) occur in the tumour bed, questioning the need for WBI. This has led to widespread adoption of accelerated partial breast irradiation (APBI) in women with early breast cancer without adverse features. IORT has seen a growing interest in early breast cancer as a modality of delivering APBI in a single fraction.

Several phase-II trials \[[@ref24], [@ref25]\] and prospective series \[[@ref6], [@ref26]\] have shown excellent early tumour control, survival, and cosmetic outcomes. Two large phase-III studies TARGIT-A (targeted intraoperative radiotherapy) \[[@ref27]\] and ELIOT (intraoperative radiotherapy with electrons) \[[@ref28]\], have evaluated the role of IORT as single-dose, partial breast irradiation treatment compared to standard, conventionally fractionated WBI for highly selected patients with relatively low-risk early-stage invasive breast cancer.

[Table 2](#table2){ref-type="table"} summarises the relevant differences in the two trials with the 5-year results. Both the Eliot and TARGIT trials demonstrated significantly higher recurrence rates compared to WBI; however, the results were reported to be within the predefined statistical margin for equivalence/non-inferiority. Also, in both the trials, fewer skin side effects were seen in the IORT group compared to those in the WBI group.

TARGIT-A trial also reported significantly lower non-breast cancer deaths in the TARGIT group (*p* = 0.0086). This difference was attributed to fewer radiotherapy-related cardiovascular deaths in the TARGIT group; however, radiotherapy-related cardiovascular deaths may not become apparent so early in the follow-up period and these differences could have resulted due to imbalance in the treatment arms \[[@ref29]--[@ref32]\]. The TARGIT-A trial has also come in for criticism related to its statistical assumptions \[[@ref33]--[@ref35]\]. Though the trial seems to show a non-inferiority in 5-year local recurrence rates, median follow-up of all randomised patients is just 29 months which is too early to make assumptions regarding local recurrence rate at 5 years and also the authors seem to have misinterpreted the non-inferiority criterion, which require the upper confidence interval (CI) be less than the predefined non inferiority level of 2.5% \[[@ref33]--[@ref35]\].

To summarise the trials of single-dose IORT, both ELIOT trial (IOERT) and TARGIT trial (kV-IORT) demonstrated a higher recurrence rate compared to WBI, although within the equivalence margin \[[@ref36]\]. TARGIT-A (KV-IORT) also requires a longer follow-up before drawing definite conclusions and adopting it for widespread use in place of WBI \[[@ref35], [@ref36]\]. It is prudent to use these techniques in a highly selected group of low-risk early-breast cancer to achieve acceptable results. Leonardi *et al* \[[@ref37], [@ref38]\] used the American Society for Therapeutic Radiation Oncology (ASTRO) consensus statement \[[@ref39]\] and the Groupe Européen de Curiethérapie--European Society for Therapeutic Radiology and Oncology (GEC--ESTRO) recommendations \[[@ref40]\] for APBI patient selection, to stratify 1822 patients treated with ELIOT outside the trial into different risk groups, 16% of women met ASTRO suitable criteria and 31% were good candidates as per GEC-ESTRO recommendations, local recurrence rates were 1.5% and 1.9%, respectively. Thirty-six per cent of women who had favourable biology disease with a luminal-A subtype also showed a very low local recurrence rate of 1.7% irrespective of the risk group. Therefore, ASTRO suitable, GEC ESTRO good and luminal-A subtype identify a subset of women, who may be safely treated with single-dose IORT with acceptable results \[[@ref36]--[@ref38], [@ref41]\].

Though it may not be time yet for IORT to replace WBI in early-breast cancer, IORT has been investigated as a strategy for boost in limited-stage breast cancer prior to WBI. Compared to post-operative boost, IORT boost allows precise delivery to a smaller target volume separated from skin, rather than to a volume distended or distorted by seroma, thus improving accuracy and cosmesis. Also, a single-shot boost treatment significantly reduces the duration of adjuvant RT. In a pooled analysis by the International Society of Intraoperative Radiotherapy (ISIORT), IOERT has been demonstrated to be an effective boost strategy with excellent local control rates \[[@ref42]\]. A total of 1109 unselected patients belonging to any of the risk groups were treated with IOERT boost (median 10 Gy) followed by WBI (50--54 Gy). At a median follow-up of 6 years, only 16 local recurrences were observed resulting in a local control rate of 99.2%. Grade was the only significant predictor of local recurrence, while none of the age groups demonstrated a higher recurrence rates. Efficacy of KV-IORT as a modality for intraoperative boost has been demonstrated in two large prospective series, an IORT boost of 18--20 Gy was followed by WBI, a local recurrence rate of 1.73% was observed in the study by Vaidya *et al* \[[@ref43]\], while a 3% recurrence rate was seen in the study by Blank *et al* \[[@ref44]\]. The TARGIT-B trial (NCT01792726), which compares EBRT boost versus an IORT boost, in patients at high risk for local recurrence who are receiving breast-conserving treatment, with standard postoperative EBRT has been launched and may provide definite answers.

IORT boost has emerged as an attractive option for boost in combination with oncoplastic surgery \[[@ref45]\]. Oncoplastic reconstruction techniques allow for a wider resection margin while maintaining the cosmetic outcome; however, an externally delivered boost, in such cases, has higher chance of partially missing the target volume due to the tissue displacement techniques used for reconstruction. IORT allows for a precise delivery of the radiation boost directly to the tumour bed during surgery and can be followed by oncoplastic reconstruction thus maintaining the oncological safety and improving cosmetic outcome, with other added advantages like avoiding seroma formation and reducing the duration of EBRT. The Breast Centre of the University Hospital of Cologne \[[@ref45], [@ref46]\] has recently reported the aesthetic outcomes of X-ray IORT boost (20 Gy) combined with oncoplastic surgery in 149 patients treated since 2011, with excellent cosmetic outcomes in over 90% and seroma formation rates of 2% at 4 weeks.

Colorectal cancers
------------------

Locally advanced rectal cancer is best managed with aggressive multimodality treatment involving chemoradiotherapy and radical resection. Most locally advanced (T3) tumours do well with this multimodality approach and local recurrences are seen in only 5--10% of patients. However, in 15% of T4 (unresectable) tumours R0 resections may not be possible \[[@ref47], [@ref48]\] and 10% of complete resections still develop local recurrences \[[@ref47], [@ref48]\] after full course chemoradiotherapy. Resection status is the most important determinant of local control and survival; incomplete resections yield few long-term survivors. There may be a case for dose escalation in locally advanced/unresectable rectal cancers with incomplete resections or at high risk of local recurrence (close margins); however, gastrointestinal tolerance limits the radiation dose delivered by EBRT. With IORT, higher doses can be delivered directly to the tumour bed without significantly increasing doses to nearby structures. This high dose may be capable of sterilising the margins even after microscopic/macroscopic residual disease.

There is increasing evidence ([Table 3](#table3){ref-type="table"}) to suggest that inclusion of IORT in the multi-modal treatment of locally advanced rectal cancer can lead to improved local control and survival \[[@ref11], [@ref49]--[@ref51]\] especially in the setting of R+ resection. IORT in locally advanced rectal cancer is commonly delivered as an intraoperative boost and used in combination with pre-operative or post-operative radiotherapy with or without chemotherapy \[[@ref11], [@ref49]\]. Most studies have utilised IOERT and others have utilised HDR IORT for delivery of IORT in rectal cancer.

[Table 3](#table3){ref-type="table"} summarises various non-randomised and randomised studies of IORT in locally advanced rectal cancers. The initial non-randomised comparisons \[[@ref52]--[@ref54], [@ref57], [@ref62]\] showed conflicting results with IORT after complete resection (*R*0), while some studies showed equivalent local control \[[@ref54]\] in IORT and non IORT group^,^ others showed a significant benefit in local control with IORT \[[@ref52], [@ref57], [@ref62]\]. One thing which is certain was that IORT provided significant benefit in local control and survival in patients with *R*+ resection \[[@ref54], [@ref55], [@ref59], [@ref61]\]. The only two randomised studies \[[@ref56], [@ref58]\] comparing the addition of IORT to standard treatment failed to show any benefit with addition of IORT in terms of local control or survival. The study by Dubois *et al*. \[[@ref58]\] had a large proportion of T3 tumours (89%), complete resection in most patients would have likely minimised the benefits of IORT, while on the other hand, the study by Masaki *et al*. \[[@ref56]\] was limited by small sample size and inclusion of T1/T2 patients.

Management of locally recurrent rectal (LRRC) cancers presents unique challenges. Prior irradiation in these patients limits the scope for further treatment of these patients with EBRT and is generally associated with poorer survival. IORT with its ability to limit the dose to critical structures serves as a reasonable technique for re-irradiation in LRRC. With the addition of IORT to gross total resection and EBRT, various initial series \[[@ref63], [@ref64]\] reported a 5-year survival of over20% even without chemotherapy.

Non-randomised studies of IORT in LRRC ([Table 4](#table4){ref-type="table"}) have shown a significant improvement in local control with IORT and many series have also shown a survival advantage. Recent series \[[@ref65]--[@ref70]\] have also employed Re-EBRT and chemotherapy along with IORT in patients previously treated with pelvic radiotherapy and were able to achieve survival in the range of 30--40%, using these aggressive strategies. Important factors affecting outcomes in most of these studies was completeness of surgical resection \[[@ref65], [@ref68]--[@ref70]\] and addition of IORT boost \[[@ref63], [@ref66], [@ref67]\]. EBRT during recurrent setting appears to improve the outcomes further and should be considered whenever feasible \[[@ref68], [@ref70], [@ref71]\].

The complication rates in these IORT studies are variable and could range anywhere between 5% and 60%. Wound complications, gastrointestinal problems, ureteric obstruction and neuropathy are some of the frequently encountered morbidities. Wound complications were most common and in some series was quite high, upwards of 40% \[[@ref50], [@ref62], [@ref72], [@ref73]\]. Gastrointestinal fistulae and ureteric damage have an incidence ranging from 2% to 12% \[[@ref50], [@ref62], [@ref64], [@ref72], [@ref73]\]. Plexopathy and neuropathy are late toxicities of pelvic IORT and have shown a dose-dependent relationship after IORT \[[@ref50], [@ref62], [@ref64], [@ref65], [@ref72], [@ref73]\]^.^

A meta-analysis \[[@ref74]\] of studies of IORT in locally advanced and recurrent rectal cancers together, has shown a significant benefit with addition of IORT on local control, disease-free survival and overall survival. Meta-analyses of complications did not demonstrate a significant increase in urologic or gastrointestinal complications; however, a greater number of wound complications did occur \[[@ref74]\].

Soft-tissue sarcomas
--------------------

Surgery constitutes the main treatment modality for soft-tissue sarcomas; however, surgery alone cannot provide acceptable local control rates without hampering the functionality of the limb/organ in cases of large and high grade sarcomas, thus making radiation therapy an integral component of function preserving surgery. Radiation therapy used either preoperatively or postoperatively provides acceptable local control rates after an adequate surgery with negative margins. However, in cases of advanced tumours where negative margin is not possible without mutilating surgery (retroperitoneal sarcoma) or in case of recurrent tumours, optimum doses of EBRT cannot be delivered to provide acceptable local control.

IORT has been used in such tumours to escalate doses beyond that of conventional EBRT in an attempt to improve local control rates. In extremity sarcomas, IORT has also been used to replace external boost, reducing the dose and volumes treated with EBRT, so that tolerance of normal structures like joint space, bone, and skin can be respected.

[Table 5](#table5){ref-type="table"} summarises studies of IORT in extremity soft-tissue sarcomas, these studies were heterogeneous with varying proportion of recurrent tumours and incomplete resections. Use of IORT in these unfavourable patients aimed at preserving the limb while maintaining acceptable local control. IORT was mostly used in combination with function preserving surgery and moderate doses of EBRT. Recent series \[[@ref82]--[@ref85]\] of IORT demonstrate excellent LC rates and functional outcomes, comparable to the series of EBRT alone, despite including higher proportion of tumours with unfavourable factors. Dose of IORT was dependant on resection status, volume and dose of EBRT. While *R*+ disease fared equally well as *R*0 disease in the series by Call *et al* and Kretzler *et al* \[[@ref79], [@ref82]\], studies by Niewald *et al* and Kretzler *et al* \[[@ref79], [@ref81]\] reported equivalent outcomes in recurrent as well as primary disease. However, in some of the larger series, \[[@ref82]--[@ref85]\] resection status and recurrent disease were the most important factors determining local control. Limb preservation was achievable in most patients even with recurrent disease. The complications of neuropathy, contracture, and lymphedema were low, wound complications were the most common complications, and were not much different from that with EBRT \[[@ref79]--[@ref82]\].

Soft-tissue sarcomas in the retro peritoneum are difficult to remove with adequate margins due to their large size, advanced stage, and difficult location with multiple critical organs in close vicinity. Therefore, surgery is often combined with radiotherapy in order to improve the local control rate. However, the proximity of normal organs, such as viscera and neurovascular structures, has made the delivery of therapeutic doses of postoperative EBRT problematic, with higher rates of gastrointestinal complications, including disabling chronic enteritis and fistulae. These difficulties have led to adoption of IORT in the treatment regimen for retroperitoneal sarcoma since the late 1980s.

A randomised trial at the NCI \[[@ref86]\], at a median follow-up of 8 years, showed a significantly better local control with IOERT and low-dose post-operative EBRT compared to high-dose post-operative EBRT alone (60% vs. 20%, *p* \< 0.05). The IOERT arm experienced significantly more peripheral neuropathy attributed in part to use of concurrent radio-sensitisers (60% vs. 5%, *p* \< 0.05), while the EBRT only arm had significantly higher GI complications. Experience from other series, summarised in [Table 6](#table6){ref-type="table"}, has also shown encouraging results with a favourable toxicity profile.

IORT in combination with pre-operative or post-operative RT has shown encouraging results \[[@ref87]--[@ref94], [@ref97], [@ref99]\]. While initial reports \[[@ref87], [@ref89], [@ref90], [@ref92]\] had higher proportion of patients receiving post-operative RT, recent series \[[@ref88], [@ref91], [@ref93], [@ref97]--[@ref99]\] mostly use pre-operative RT because of the smaller volumes that are required with reduced rates of complications. Combination of pre-operative RT, gross total resection and IORT has demonstrated improved local control \[[@ref91], [@ref98]\] as well as survival \[[@ref88], [@ref91]\] compared to the non-IORT regimens in some of the recent non-randomised comparisons. Resection status and recurrent disease were the most important determinants for local control \[[@ref89], [@ref92], [@ref94], [@ref97]\]. GI toxicities, neuropathy and ureteric stenosis are the most common complications with reported rates of 10--35%. They may be dose-dependent, high single dose resulting in greater risk of complications \[[@ref65], [@ref86], [@ref100]\].

Most studies of IORT shown in [Tables 5](#table5){ref-type="table"} and [6](#table6){ref-type="table"} had a large proportion of recurrent tumours, emphasising the fact that IORT plays a pivotal role in the management of these locally recurrent sarcomas. In a multi-centric, long-term outcomes analysis by the Spanish Cooperative Initiative \[[@ref101]\] for Intraoperative electron radiotherapy, 103 patients were investigated to analyse long-term outcomes of locally recurrent soft-tissue sarcoma (LR-STS) patients treated with a multidisciplinary approach. The 5-year IORT in-field control, disease-free survival (DFS), and overall survival were 73%, 43%, and 52%, respectively. Not combining EBRT with surgical resection and IOERT in patients with LR-STS was associated with a significantly increased probability of LR and IOERT in-field relapse. They concluded that low rate of severe toxic events suggests that a multimodality approach with re-resection and IOERT is feasible without prohibitive long-term side effects.

Paediatric tumours
------------------

Most paediatric tumours are radiosensitive and radiotherapy constitutes an integral component in their management schema, more so for the unresectable and recurrent tumours, where outcomes remain dismal with chemotherapy alone. However, the use of radiotherapy, especially EBRT in the paediatric population is fraught with late effects like retarded bone and soft tissue growth, abnormal organ development and the risk of second malignancies due to the sensitive nature of these maturing tissues. Thus, there is a narrow therapeutic window within which local control and late effects, which needs to be balanced. The goal of IORT for paediatric tumours is to improve the therapeutic ratio by increasing local control while limiting these late toxicities.

[Table 7](#table7){ref-type="table"} summarises various studies of IORT in paediatric tumours, though the numbers are small, IORT has been used across a wide variety of sites and histologies, as a sole radiation modality for radio-sensitive tumours like neuroblastoma \[[@ref102]\] or in combination with EBRT for dose escalation to improve local control in sarcomas \[[@ref103]\] or for dose de-escalation in RMS with low-dose EBRT. Oertel \[[@ref103]\], Goodman \[[@ref104]\] and Sole \[[@ref105]\] *et al* included quite a number of recurrent tumours. Use of IORT in combination with surgery and EBRT provided excellent local control across most studies with acceptable toxicity.

In a study by Sole \[[@ref105]\] *et al*, after a median follow-up of 72 months (range, 4--10 months), 10-year LC, disease-free survival, and OS was 74%, 57%, and 68%, respectively. In multivariate analysis after adjustment for other covariates, disease status (*p* = 0.04 and *p* = 0.05) and resection margin status (*p* \< 0.01 and *p* = 0.04) remained significantly associated with LC and OS.

IOERT can be considered as an effective option as a part of multimodality regimen for paediatric solid malignancies, especially for patients with recurrent tumours and abdominopelvic malignancies.

Gynaecological cancers
----------------------

Recurrent gynaecological malignancies are associated with poor survival due to lack of effective salvage options. Survival rates of locally recurrent cervical cancer after prior radiation therapy are dismal. Most recurrences especially those involving the pelvic sidewall are not resectable and when resection is possible (as in central recurrences), extensive procedures like pelvic exenteration are required, which are associated with a high rate of complications and operative mortality of over 10% \[[@ref108]--[@ref111]\]. Introduction of IORT has widened the scope of patients who may be offered surgery and patients who have been previously treated with non-surgical modalities can be offered radical resection when combined with IORT. In resectable recurrences, IORT given after gross total resection can improve local control rates.

IORT has been used to treat locally advanced primary cervical cancers also; however, these series \[[@ref112]\] are small and most of the experience comes from recurrent cancers ([Table 8](#table8){ref-type="table"}). IORT has shown to improve local control and thus survival in locally recurrent cancers \[[@ref113]--[@ref121]\] of the uterine cervix and endometrium, limited locoregional recurrences from endometrial cancers doing much better than recurrences from cervical cancers \[[@ref119], [@ref122]--[@ref124]\]. The benefit of IORT is seen much more in patients with microscopic residual disease than in those with gross residual disease \[[@ref113]--[@ref115], [@ref121]\]. Patient selection based on resection status and volume of recurrence are the most important factors determining outcome after IORT. Previously, irradiated patients when adjusted for resection status and volume of recurrence appear to fare as well as previously un-irradiated patients \[[@ref115]\] and addition of EBRT to IORT regimen further improves the control rates \[[@ref117], [@ref119], [@ref120], [@ref123]\]. IORT does not seem to increase the rate of acute complications following surgery. Neuropathy and gastrointestinal toxicity are the most common IORT-related toxicities and occur in 5--30% of patients.

Genitourinary cancers
---------------------

### Bladder cancer

Although multiple reports of perioperative brachytherapy in bladder cancer are available with encouraging results, there is limited data on IORT in bladder cancer, with only one small retrospective series in recurrent bladder cancer meeting our search and selection criteria. Recurrent bladder tumours after a cystectomy are associated with dismal survival rates, owing to the fact that adequate surgery is often not feasible and salvage with high doses of EBRT is difficult due to the tolerance of adjacent organs. IORT is used to deliver high doses to the tumour in an effort to improve local control. Hallemeier *et al* \[[@ref128]\] reported the use of IOERT in 17 patients after maximal resection of disease. Pre- or post-operative EBRT was used in 94% of patients. Encouraging 2-year local control and survival was seen, completely resected tumours were associated with a significant improvement in survival compared to gross residual disease.

### Renal cancer

Radical surgery forms the mainstay of treatment in patients with renal cell carcinoma (RCC). However, in patients with recurrent and advanced tumours, achieving complete resection with wide margins may be difficult due to proximity to the critical structures and this effects not only the local control but survival as well \[[@ref129]\]. Adjuvant EBRT in this setting may improve local control; however, the doses achievable with EBRT is limited due to low tolerance of the surrounding structures like stomach, small bowel, contralateral kidney, liver, and spinal cord. IORT offers an attractive treatment option to escalate doses to the tumour bed, especially in cases with positive resection margins. Studies evaluating the role of IORT in the management of locally advanced and recurrent RCC are summarised in [Table 9](#table9){ref-type="table"} \[[@ref129]--[@ref134]\].

Habl *et al* \[[@ref132]\] reported outcomes with IOERT after complete surgical resection in a cohort of 17 patients with locally recurrent RCC. Although R0 resection could be achieved in only one-third of the patients, most patients failed distally, with only two local recurrences. None of the patients suffered from any acute or late radiation toxicities. One of the largest series of IOERT in RCC has been reported by Paly *et al* in a multi-institutional cohort of 98 patients. Twenty-eight per cent patients had advanced disease at presentation and 72% had recurrent disease. More than 50% had residual disease after resection. Sixty-two per cent received additional pre-operative or post-operative EBRT. An excellent local control of 72% at 5 years was demonstrated with grade 3 toxicity in 5% of patients. Higher IORT dose was associated with improved survival (*p* \< 0.001). Thus, studies of IORT in RCC, though retrospective in nature demonstrate a consistently high local control rate in recurrent/advanced RCC with acceptable toxicity rates.

### Prostate cancer

Locally advanced/high-risk prostate cancer is associated with significant risk of relapse when treated with radical prostatectomy alone, risk being the highest when the margins are positive. Adjuvant radiotherapy in this setting reduces the risk of relapse significantly \[[@ref135]\]. IORT has been explored in high-risk prostate cancers in combination with radical prostatectomy and post-operative EBRT to improve local control via dose escalation. IORT has the added radiobiological advantage of high single dose of radiation, which improves the therapeutic gain due to low α/β of prostate. It also helps limit doses to the rectum and has been shown to have low gastrointestinal (GI) morbidity even in combination with EBRT \[[@ref136]\]. Several small prospective series ([Table 10](#table10){ref-type="table"} \[[@ref136]--[@ref141]\]) have evaluated the feasibility of this multi-modality approach in patients with non-metastatic, node-negative disease with probability of LN involvement being less than 15%. Encouraging local control and acceptable toxicity has been demonstrated even though significant proportion of patients had margin positive disease in these series \[[@ref136], [@ref139], [@ref141]\]; however, long-term results are awaited.

Upper gastro-intestinal tumours
-------------------------------

### Gastric cancers

Curative resection is the mainstay of treatment for gastric cancer; however, high incidence of locoregional and systemic failures, makes outcomes dismal, especially in cases with gastric serosal involvement and/or nodal involvement \[[@ref142], [@ref143]\]. Attempts to improve locoregional control and survival include addition of adjuvant radiotherapy/chemoradiation \[[@ref144]\], perioperative chemotherapy \[[@ref145]\] and extensive surgeries including D2/D3 resections \[[@ref146], [@ref147]\]. Despite significant improvements in disease control and survival with adjuvant chemoradiotherapy, local and regional recurrences remain high at 19% and 65%, respectively, after tri-modality therapy \[[@ref144]\]. Therefore, there may be a case for dose escalation with IORT in advanced gastric carcinomas (especially serosal/nodal involvement) to improve local/regional control. IORT in gastric cancer involves boosting the tumour bed, remaining lymphatic networks, and nodal basins to control residual microscopic disease and improve locoregional control.

Role of IORT in gastric cancer after curative resection has been evaluated in multiple studies (retrospective, prospective, and randomised control), which have shown an improvement in locoregional control \[[@ref148], [@ref150]\] and survival with IORT, especially in patients with stage-II/stage-III and node-positive disease ([Table 11](#table11){ref-type="table"}) \[[@ref1], [@ref148], [@ref150]--[@ref154]\]. While initial studies of IORT involved less aggressive surgeries (D1) and infrequent use of adjuvant radiotherapy recent studies \[[@ref148], [@ref150], [@ref153]\] have demonstrated a consistent benefit with IORT, even in combination with D2 resections and post-operative CTRT. Extended resections like D3 may reduce the benefit with IORT \[[@ref153]\], however, IORT combined with a limited lymph node dissection (D1) may be associated with survival similar to extended dissection (D2/3), with lesser post-operative mortality \[[@ref156]\]. While most studies did not show an increase in complications with the use of IORT, Drognitz *et al* \[[@ref151]\] have demonstrated a significant increase in surgical complications with the use of IORT (44% vs. 20%, *p* \< 0.05). They also did not show a benefit with addition of IORT to surgical resection. Complication rates need to be carefully weighed against improvement in locoregional control to maximise benefits with IORT \[[@ref157]\].

### Pancreatic cancer

Pancreatic cancer is associated with dismal survival rates even in completely resected patients. Significant proportion of patients either develop locoregional recurrence or systemic metastases. Multi-modality treatment approaches combining chemotherapy and radiotherapy in addition to surgery have resulted in some improvement in locoregional control and survival \[[@ref162]--[@ref164]\]. Attempts at radiotherapy dose escalation with EBRT have been limited due to the location of tumour. IORT can result in delivery of higher doses to the tumour bed and may improve local control and survival in resected pancreatic cancers. In unresectable tumours, IORT alone or in combination with EBRT can provide some local control along with effective palliation of symptoms.

Studies of IORT in resectable pancreatic cancers are summarised in [Table 12](#table12){ref-type="table"} \[[@ref165]--[@ref171]\], though heterogeneous in proportion of *R*1 resections and use of adjuvant EBRT and/or chemotherapy, they have been consistent in showing an improvement in locoregional control \[[@ref165]--[@ref168]\]. Some studies have also shown an improvement in survival \[[@ref165], [@ref168], [@ref172], [@ref173]\]. Addition of IORT to standard treatment did not result in any increase in perioperative morbidity or late toxicity rates \[[@ref165], [@ref167]--[@ref169], [@ref173]\]. Stage \[[@ref172], [@ref173]\], *R*0 resection \[[@ref166]\], chemotherapy \[[@ref170]\], and pre-operative treatment \[[@ref168]\] were other important determinants of survival in these studies. A systematic review also agreed with observations from these non-randomised studies and suggested a survival benefit with IORT in resected pancreatic patients.

Studies of IORT in unresectable pancreatic cancer ([Table 12](#table12){ref-type="table"} \[[@ref174]--[@ref180]\]) on the other hand, have failed to demonstrate a survival benefit with the addition of IORT, though an improved local control was seen \[[@ref174]--[@ref176], [@ref178], [@ref181]\]. IORT also resulted in significant pain relief and palliation of symptoms \[[@ref175], [@ref177]--[@ref179]\] with no additional morbidity or toxicity \[[@ref175], [@ref177], [@ref181]\]. Tumour size \[[@ref17], [@ref174], [@ref176], [@ref180]\], metastasis \[[@ref179]\], and chemotherapy \[[@ref17], [@ref174], [@ref176]\] were predictors of survival in these studies of unresectable pancreatic cancer. Most of these studies included patients treated before the year 2000 and utilised post-operative radiotherapy and chemotherapy with older regimes. In the current era, pre-operative chemotherapy (± radiotherapy) with novel systemic agents (like FOLFIRINOX and nab-Paclitaxel) has shown to improve resectablity rates and survival in unresectable pancreatic cancers \[[@ref182], [@ref183]\]. Keane *et al* \[[@ref181]\], evaluated the role of IORT in combination with intensive neoadjuvant chemoradiotherapy regimens and demonstrated encouraging survival rates in patients with close/positive margins and unresectable disease with no increase in toxicity. Further studies are required to better define the role of IORT in the management of pancreatic cancers, in the current era especially with the advent of novel systemic agents.

Conclusion
==========

Intraoperative radiation therapy is an attractive treatment option for patients with colorectal, gynaecological, intra-abdominal, head and neck, and most recently, breast cancers. IORT has been used in a multitude of roles across these sites, for dose escalation, EBRT dose de-escalation, as sole radiation modality in early-breast cancers and as a Re-irradiation modality in recurrent cancers. IORT serves its role best in combination with gross total resection and moderate doses of EBRT. Utility of IORT has been tested in the setting of a randomised control trial in early breast, retroperitoneum, gastric and colorectal cancers, the results of which support the use of IORT as a management option in these settings. However, appropriate technique and patient selection is the key to success with IORT. IORT has the potential to improve outcomes in recurrent cancers of the pelvis, head and neck and colorectum and can be considered as a supplement to gross total resection. In paediatric tumours, IORT serves to decrease late toxicities associated with EBRT. In appropriately selected patients, complication rates associated with IORT are low.

###### Studies of IORT in recurrent head and neck cancer after gross total resection.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                          Sample size            Study design                      IORT type   IORT dose (Gy)   Prior RT (%)   Adj. RT (%)   Median follow-up   LC (%)        OS (%)        Toxicity grade 3 or \>
  ------------------------------------ ---------------------- --------------------------------- ----------- ---------------- -------------- ------------- ------------------ ------------- ------------- -----------------------------------------------------------
  Scala *et al* 2013 \[[@ref20]\]      76 (100% recurrent)    Retrospective                     HDR IORT    10--17.5         71             24            11                 62 (2yr)      42 (2yr)      Total -6%\
                                                                                                                                                                                                         Neuropathy-1[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Wound-1[^\*^](#table1-fn1){ref-type="table-fn"}

  Ziedan *et al* 2012 \[[@ref21]\]     96 (48% recurrent)     Retrospective (parotid cancers)   IOERT       15--20           55             57            67                 68.5 (3yr)    66.1 (3yr)    Total -27%\
                                                                                                                                                                                                         Fistula-4[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         ORN-4[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Neuropathy-1[^\*^](#table1-fn1){ref-type="table-fn"}

  Ziedan *et al* 2011 \[[@ref22]\]     231 (89% recurrent)    Retrospective                     IOERT       15--20           81             21            12                 55 (3yr)      34 (3yr)      Total-27%\
                                                                                                                                                                                                         ORN-8[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Neuropathy-8[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Fistulas-20[^\*^](#table1-fn1){ref-type="table-fn"}

  Perry *et al* 2010 \[[@ref19]\]      34(100% recurrent)     Retrospective                     HDR IORT    10--20           100            15            23                 56 (2yr)      55 (2yr)      Total-29%\
                                                                                                                                                                                                         Wound-3[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         ORN-1[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Neuropathy-1[^\*^](#table1-fn1){ref-type="table-fn"}

  Chen *et al* 2007 \[[@ref17]\]       137 (100% recurrent)   Retrospective                     IOERT       10--18           83             26            41                 61 (3yr)      36 (3yr)      Total-6%\
                                                                                                                                                                                                         Wound-4[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Fistula-2[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Neuropathy-1[^\*^](#table1-fn1){ref-type="table-fn"}

  Pinheiro *et al* 2002 \[[@ref23]\]   34- SCC 10- non-SCC    Retrospective                     IOERT       12.5--22.5       64             36            75.6 for living\   46 52 (2yr)   32 50 (2yr)   Total-7%\
                                                                                                                                                          patients                                       Fistula-1[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Neuropathy-1[^\*^](#table1-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                         Carotid blowout-1[^\*^](#table1-fn1){ref-type="table-fn"}

  Nag *et al* 1998 \[[@ref18]\]        38 (100% recurrent)    Retrospective                     IOERT       15--20           100            0             30                 19 (1yr)      21% (1yr)     Total -16%\
                                                                                                                                                                                                         Fistula-2[^\*^](#table1-fn1){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Adj. RT: Adjuvant post-IORT RT, LC: local control, OS: overall Survival,

Number of patients.

###### Randomised control trials of IORT versus WBI in early-breast cancer.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial name               Sample size                        Age           Inclusion criteria                    IORT type                  IORT dose                                                Trial design                                                            Local recurrence (5yr)            Overall survival/mortality (5yr)
  ------------------------ ---------------------------------- ------------- ------------------------------------- -------------------------- -------------------------------------------------------- ----------------------------------------------------------------------- --------------------------------- ----------------------------------
  ELIOT \[[@ref28]\]       1305 median follow-up: 5.8 years   \> 48 years   any invasive cancer \< 2.5 cm         IOERT                      ELIOT:21 Gy/1\# to tumour bed with 6--9 MeV electrons\   Equivalence trial:\                                                     ELIOT:4.4% (95% C.I: 2.7--6.1)\   ELIOT:96.8%\
                                                                                                                                             WBI:50 Gy/25\# + 10 Gy/5\# boost                         Statistical margin was local recurrence of 7.5% in the IORT group       WBI: 0.4%\                        WBI: 96.9%\
                                                                                                                                                                                                                                                                              *p* \< 0.0001                     

  TARGIT-A \[[@ref27]\]\   3451 Median follow-up:\            \> 45years    T1-2, N0, 1 IDC \< 3.5 cm\            X-ray IORT (50 kv X-ray)   TARGIT: 20 Gy to tumour bed\                             Non-inferiority trial:\                                                 TARGIT:3.3% (95% CI: 2.1--5.1)\   TARGIT:3.9%\
                           2.5 years                                        (If EIC or ILC on final histology,\                              5--7 Gy at 1 cm depth\                                   Statistical margin was 2.5% difference in local recurrence at 5 years   WBI:1.3%\                         WBI: 5.3\
                                                                            add whole breast RT)                                             WBI: 40--56 Gy with or without boost 10--16 Gy                                                                                   (95% CI: 0.7--2.5)\               *p* = 0.009\
                                                                                                                                                                                                                                                                              *p* = 0.042                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EIC: extensive intraductal component, ILC: invasive lobular cancer, WBI: whole breast RT.

###### Studies of IORT in locally advanced colorectal cancer after gross total resection.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                              Sample size   Study design      T4 %    IORT type   IORT dose (Gy)   EBRT %             Median F/U   LC 5 year (%)               OS 5 year (%)         Toxicity grade 3 or \>
  ---------------------------------------- ------------- ----------------- ------- ----------- ---------------- ------------------ ------------ --------------------------- --------------------- -------------------------------------------------------
  Ratto *et al*. \[[@ref52]\] 2003         43\           NRC               93      IOERT       10--15           100                74           Sx + IORT: 91\              61                    NR for IORT patients
                                           IORT-19\                                                                                             Sx − 57\                                          
                                           No IORT-24                                                                                           *p* = 0.035                                       

  Sadahiro *et al*. \[[@ref53]\] 2004      IORT-99\      NRC               12      IOERT       15--25           100 (20 Gy only)   67\          Sx + IORT-98\               Sx + IORT- 79\        NR for IORT patients
                                           No IORT-68                                                                              83           Sx- 84\                     Sx- 58\               
                                                                                                                                                *p* = 0.002                 *p* = 0.002           

  Ferenschild *et al*. \[[@ref54]\] 2006   123\          NRC               25      HDR-IORT    10               100                25           R0+IORT:72\                 R0+IORT:56\           NR for IORT patients
                                           IORT-30\                                                                                             R0:71 (N.S diff)\           R0:66 (N.s diff)\     
                                           No IORT-93                                                                                           *R*^(+)^ + IORT:58\         *R*+ ( + ) IORT:38\   
                                                                                                                                                *R* ^(+)^:0 (*p* = 0.016)   *R*+:0 (*p=* 0.026)   

  Roeder *et al*. \[[@ref55]\] 2007        243           RC                20      IOERT       10--15           86                 59           R0 + IORT- 94\              NR                    Total-10%\
                                                                                                                                                *R*^(+)^ + IORT-72                                Proctitis-8\
                                                                                                                                                                                                  Fistula-7\
                                                                                                                                                                                                  Bowel stenosis-8

  Mathis *et al*. \[[@ref50]\] 2008        146           PC                64      IOERT       7.5--25          100                44           86                          52                    Total- 22%\
                                                                                                                                                                                                  Neuropathy-3[^\*^](#table3-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                  GI/GU-23[^\*^](#table3-fn1){ref-type="table-fn"}

  Masaki *et al*. \[[@ref56]\] 2008        44\           RCT               0       IOERT       18--20           No                 34           Sx+IORT-94.7\               *p =* 0.344\          Urinary catheter indwelling 29% vs. 3%,\
                                           IORT-19\                                                                                             Sx-95.5%                    N.s diff              Rest- N.s diff
                                           No IORT-25                                                                                                                                             

  Valentini *et al*. \[[@ref57]\] 2009     100\          NRC               100     IOERT       10--15           100                31           R0+IORT:100\                NR                    NR for IORT patients
                                           IORT-29\                                                                                             R0:81\                                            
                                           No IORT-71                                                                                           *p* = 0.014                                       

  Dubois *et al* \[[@ref58]\] 2008         142\          RCT               100     IOERT       15--18           100                60           Sx + IORT- 91.8\            Sx + IORT - 69.8\     No difference in toxicity *p*=0.15
                                           IORT-73\                                                                                             Sx- 92.8\                   Sx- 74.8\             
                                           No IORT-69                                                                                           *p* = 0.6018                *p*=0.25              

  Kusters *et al* \[[@ref59]\] 2010        605           PC\               29      IOERT       10--12.5         100                             R0+IORT- 90.5\              67                    NR
                                                         Pooled analysis                                                                        *R*^(+)^ + IORT-55\                               
                                                                                                                                                *p* \< 0.001                                      

  Sole *et al*. \[[@ref60]\] 2014          335           PC                16      IOERT       10--15           100                72.6         92                          75                    Total-10%\
                                                                                                                                                                                                  GI-19[^\*^](#table3-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                  GU-8[^\*^](#table3-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                  Neuropathy-7[^\*^](#table3-fn1){ref-type="table-fn"}

  Holman *et al* \[[@ref61]\] 2016         417           PC\               100%\   IOERT       10--12.5         97                 52           *R*0 + IORT- 87\            *R*0 + IORT-65\       NR
                                                         Pooled analysis   T4                                                                   *R*1 + IORT- 60\            *R*1 + IORT- 34\      
                                                                                                                                                *R*2 + IORT- 57\            *R*2 + IORT- 14\      
                                                                                                                                                *p* \< 0.001                *p* \< 0.001          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NRC: non randomised comparison, RCT: randomised controlled trial, PC: prospective cohort, RC: retrospective cohort, F/U: follow-up, Sx: surgery, *R*^(+)^: residual after surgery, LC:-local control, OS:-overall Survival, NR: not reported,

Number of patients,

N.s diff: Non significant difference.

###### studies of IORT in locally recurrent colorectal cancers.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                            Sample size   Study design         IORT type   IORT dose (Gy)   Prior EBRT %   Adj. EBRT %   Median Follow up   LC 5year (%)                        OS 5year (%)                    Toxicity grade 3 or \>
  -------------------------------------- ------------- -------------------- ----------- ---------------- -------------- ------------- ------------------ ----------------------------------- ------------------------------- ---------------------------------------------------------------
  Suzuki *et al*. \[[@ref63]\] 1995      106\          NRC                  IOERT       10--30           25             98            44                 Sx+IORT:60%\                        Sx+IORT:19\                     Total-36%\
                                         Sx+IORT:42\                                                                                                     Sx:7%\                              Sx: 7%\                         Abcess-5\
                                         Sx:64                                                                                                           at 3years                           P=0.0006                        GI/GU-9\
                                                                                                                                                                                                                             wound-3

  Valentini *et al*. \[[@ref66]\] 1999   47\           NRC                  IOERT       10--15           28             100           80                 Sx+IORT:80\                         Sx+IORT:41\                     Hydronephrosis-1\
                                         Sx+IORT:11\                                                                                                     Sx:24\                              Sx:16\                          Neuropathy-0[^\*^](#table4-fn1){ref-type="table-fn"}
                                         Sx:14                                                                                                           *p* \< 0.05                         N.S diff                        

  Alektiar *et al*. \[[@ref75]\] 2000    74            RC                   HDR-IORT    10--18           53             39            22                 *R*0+IORT- 43\                      *R*0+IORT-36\                   Fistula-8[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                         *R*^(+)^ +IORT-26\                  *R*^(+)^ +IORT-11\              Neuropathy-1[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                         *p* = 0.02                          *p* = 0.04                      Ureter-10[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                             Wound-5[^\*^](#table4-fn1){ref-type="table-fn"}

  Lindel *et al*. \[[@ref76]\] 2001      IORT-49\      NRC                  IOERT       10--20           14             94            NR                 *R*0 + IORT-56\                     *R*0 + IORT-40\                 Wound complication-4[^\*^](#table4-fn1){ref-type="table-fn"}\
                                         No IORT-20                                                                                                      *R*^(+)^ +IORT-14\                  *R*^(+)^+IORT-17\               Neuropathy-4[^\*^](#table4-fn1){ref-type="table-fn"}

  Wiig *et al*. \[[@ref67]\] 2002        107\          NRC                  IOERT       15--20           0              100           NR                 Sx+IORT:50\                         Sx+IORT:30\                     late toxicity: NR\
                                         Sx+IORT:59\                                                                                                     Sx: 30\                             Sx: 30%\                        Acute complication: N.s diff
                                         Sx:48                                                                                                           N.S diff                            N.S diff                        

  Dresen *et al* \[[@ref69]\]. 2008      147           RC                   IOERT       10.--17.5        53             84            NR                 *R*0 + IORT-69\                     *R*0 + IORT-59\                 Neuropathy-16[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                         *R*1 + IORT-29\                     *R*1 + IORT-27\                 Ureter stenosis-4[^\*^](#table4-fn1){ref-type="table-fn"}
                                                                                                                                                         *R*2 + IORT-28 *p* \< 0.001(3yr)    *R*2 + IORT-24\                 
                                                                                                                                                                                             *p* \< 0.001(3yr)               

  Haddock *et al*. \[[@ref65]\] 2011     607           PC                   IOERT       7.5--30          45             96            44                 *R*0 + IORT-79\                     *R*0 + IORT-46\                 Total-11%\
                                                                                                                                                         *R*1 + IORT-56\                     *R*1 + IORT-27\                 Wound-42[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                         *R*2 + IORT-49\                     *R*2 + IORT-16\                 Neropathy-18[^\*^](#table4-fn1){ref-type="table-fn"}
                                                                                                                                                         *p* \< 0.001                        *p*\< 0.001                     

  Roeder *et al*.\[[@ref70]\] 2012       97            PC                   IOERT       10--20           44             52            33                 *R*0 + IORT-82\                     *R*0 + IORT-80\                 Acute:\
                                                                                                                                                         *R*1 + IORT-41\                     *R*1 + IORT-37\                 Abscess /fistula-16\
                                                                                                                                                         *R*2 + IORT-18\                     *R*2 + IORT-35\                 Late:\
                                                                                                                                                         *p* \< 0.001(3yr)                   *p* \< 0.001(3yr)               Neuropathy-8[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                             Ureter stenosis-3[^\*^](#table4-fn1){ref-type="table-fn"}

  Calvo *et al*. \[[@ref68]\] 2013       60            RC                   IOERT       10--15           50             47            36                 44\                                 43\                             Total:42%\
                                                                                                                                                         *R*0 vs *R*1: HR-2.09, *p* = 0.05   *R*0 vs R1:HR-2.9, *p* = 0.05   Fistula-4[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                             Neuropathy-4[^\*^](#table4-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                             GI-4[^\*^](#table4-fn1){ref-type="table-fn"}

  Holman *et al*. \[[@ref71]\] 2017      565           PC pooled analysis   IOERT       10--20           46             95            40 months\         *R*0 + IORT-72\                     *R*0 + IORT-48\                 
                                                                                                                                      In survivors       *R*1 + IORT-36\                     *R*1 + IORT-25\                 
                                                                                                                                                         *R*2 + IORT-39\                     *R*2 + IORT-17\                 
                                                                                                                                                         *p* \< 0.0001                       *p* \< 0.0001                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NRC: non randomised comparison, RCT: randomised controlled trial, PC: prospective cohort, RC: retrospective cohort, Sx: surgery, *R*^(+)^: residual after surgery, *R*0: no residual after surgery, LC: local control, OS: overall survival, NR: not reported,

Number of patients,

N.s diff: non-significant difference.

###### Studies of IORT in extremity soft tissue sarcoma in combination with function preserving surgery and moderate doses of EBRT (40-50Gy).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                                                             Sample size                    Study design           IORT type        IORT dose Gy   EBRT %   Median follow-up   LC 5 year                                   DFS 5 year   OS 5 year   Complications
  ----------------------------------------------------------------------- ------------------------------ ---------------------- ---------------- -------------- -------- ------------------ ------------------------------------------- ------------ ----------- ----------------------------------------------------------------
  Edmonson *et al*. \[[@ref77]\] 2001                                     39 (Recurrent-3%, *R*+:38%)    Retrospective          IOERT/HDR IORT   10--20         100      70                 90[^α^](#table5-fn3){ref-type="table-fn"}   NR           80          NR for IORT

  Azinovic *et al*. \[[@ref78]\] 2003                                     45 (Recurrent-42%, *R*+:33%)   Retrospective          IOERT            10--20         80       93                 80\                                         NR           64          Wound complication -4[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                            *R*0 vs *R*1:\                                                       Neuropathy-5[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                            88 vs 57\                                                            Fracture-2[^\*^](#table5-fn1){ref-type="table-fn"}
                                                                                                                                                                                            *p* = 0.04                                                           

  Kretzler *et al*. \[[@ref79]\] 2004                                     28\                            Retrospective          HDR/IOERT        12--15         90       55                 84                                          54           66          Total-24%\
                                                                          (Recurrent -57%, *R*+:39%)                                                                                                                                                             Neuropathy-1[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                 Fractures-2[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                 Contracture-2[^\*^](#table5-fn1){ref-type="table-fn"}

  Oertel *et al*. \[[@ref80]\] 2006                                       153\                           Retrospective          IOERT            10--20         100      33                 78                                          NR           77          Wound-17%\
                                                                          (Recurrent - 38%, *R*+: 30%)                                                                                                                                                           Neuropathy-7[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                 Lymphededma-6[^\*^](#table5-fn1){ref-type="table-fn"}

  Niewald *et al*. \[[@ref81]\] 2009                                      38\                            Retrospective          HDR-IORT         8--15          100      27                 63                                          NR           57          Skin-42%\
                                                                          (Recurrent -24%,)                                                                                                                                                                      Neuropathy-0

  Call *et al*. \[[@ref82]\] 2012 [¥](#table5-fn2){ref-type="table-fn"}   61\                            Retrospective          IOERT            7.5--20        100      70                 91                                          80           72          Wound-3.2%\
                                                                          (Recurrent -21%, *R*+:18%)                                                                                                                                                             Neuropathy-1[^\*^](#table5-fn1){ref-type="table-fn"}

  Calvo *et al*. \[[@ref83]\] 2014                                        159\                           Retrospective pooled   IOERT            10--20         100      53                 82\                                         62           72          Acute skin/wound- 16%\
                                                                          (*R*1-16%)                                                                                                        *R*0 vs *R*1:\                                                       Neuropathy-6[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                            *p* = 0.009                                                          Lympedema-7[^\*^](#table5-fn1){ref-type="table-fn"}

  Roeder *et al*. \[[@ref84]\] 2014                                       34\                            Prospective            IOERT            10--15         100      43                 97\                                         66           79          Neuropathy-1[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                          (*R*1-12%)                                                                                                                                                                             osteonecrosis-1[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                 Joint dysfunction-1[^\*^](#table5-fn1){ref-type="table-fn"}

  Roeder *et al*. \[[@ref85]\] 2016                                       183\                           Retrospective          IOERT            8--20          100      64                 86\                                         61           77          Total-19%\
                                                                          (Recurrent -22%, *R*1 - 32%)                                                                                      *R*0 vs *R*1: 92 vs 75 *p* = 0.019                                   Wound-15[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                 Neuropathy-14[^\*^](#table5-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                 osteonecrosis-11[^\*^](#table5-fn1){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*R*+: Residual after surgery, *R*0: no residual after surgery, LC: local control, OS: overall Survival, DFS: disease-free survival, NR: not reported,

Number of patients,

call *et al* included only upper extremity tumours,

-crude rate

###### Studies of IORT in Retroperitoneal sarcoma.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                             Sample size               Study design                 IORT type   IORT dose (Gy)   EBRT %   Median follow-up   LC 5 year (%)                                    OS 5 year (%)                                    Toxicity grade 3 or \>
  --------------------------------------- ------------------------- ---------------------------- ----------- ---------------- -------- ------------------ ------------------------------------------------ ------------------------------------------------ -------------------------------------------------------------
  Sindelar *et al*. \[[@ref86]\] 1993     35\                       RCT\                         IOERT       20               100      96                 IORT + PORT- 60%'\                               \-                                               Neuropathy\
                                          GTR-100%                  Sx + IORT + low-dose PORT\                                                            PORT-20%                                                                                          IORT + PORT-60%\
                                                                    Vs Sx + high-dose PORT                                                                                                                                                                  PORT-5%\
                                                                                                                                                                                                                                                            Enteritis\
                                                                                                                                                                                                                                                            IORT + PORT-13%\
                                                                                                                                                                                                                                                            PORT-50%

  Alektiar *et al*. \[[@ref87]\] 2000     32\                       Retrospective cohort         HDR-IORT    12--15           78       33                 62                                               45                                               GI -18%\
                                          Recurrent -62%, GTR-94%                                                                                                                                                                                           Neuropathy-0%

  Gieschen *et al*. \[[@ref88]\] 2001     37\                       Retrospective cohort         IOERT       10--20           \        38                 \                                                \                                                Total-20%\
                                          IORT-20\                                                                            100\                        IORT-83\                                         IORT-74\                                         Neuropathy-1[^\*^](#table6-fn1){ref-type="table-fn"}\
                                          No IORT-17\                                                                         100                         No IORT-61\                                      No IORT-30\                                      Fistula-2[^\*^](#table6-fn1){ref-type="table-fn"}
                                          Recurrent-22%\                                                                                                  p = 0.197[¥](#table6-fn2){ref-type="table-fn"}   p = 0.044[¥](#table6-fn2){ref-type="table-fn"}   
                                          GTR-78%                                                                                                                                                                                                           

  Peterson *et al* \[[@ref89]\] 2002      87\                       Retrospective cohort         IOERT       8.75--30         89       42                 59                                               47                                               GI-14%\
                                          Recurrent-50%, GTR-84%                                                                                                                                                                                            Neuropathy- 10%

  Bobin *et al*. \[[@ref90]\] 2003        24\                       Retrospective cohort         IOERT       8--22            92       53                 46                                               56                                               Total-8%\
                                          Recurrent-79%\                                                                                                                                                                                                    Neuropathy-2[^\*^](#table6-fn1){ref-type="table-fn"}
                                          GTR-92                                                                                                                                                                                                            

  Pierie *et al*. \[[@ref91]\] 2006       IORT-14\                  Retrospective cohort         IOERT       10--20           100\     27                 NR                                               IORT-77\                                         GI-1%\
                                          No IORT-27\                                                                         100                                                                          No IORT-45\                                      Neuropathy-3%
                                          Recurrent-0%\                                                                                                                                                    *p* = 0.38                                       
                                          GTR-100%                                                                                                                                                                                                          

  Krempien *et al*. \[[@ref92]\] 2006     67\                       Retrospective cohort         IOERT       12--20           67       30                 40                                               64\                                              Fistula-3[^\*^](#table6-fn1){ref-type="table-fn"}\
                                          Recurrent-61%, GTR-82%                                                                                                                                           *R*0:87\                                         Neuropathy-5[^\*^](#table6-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                           *R*+:50\                                         Urethral stenosis-2[^\*^](#table6-fn1){ref-type="table-fn"}
                                                                                                                                                                                                           *p* \< 0.01                                      

  Pawlik *et al*. \[[@ref93]\] 2006       72\                       Prospective cohort           IOERT       15               100      40                 60[¥](#table6-fn2){ref-type="table-fn"}          50                                               NR
                                          IORT-22\                                                                                                                                                                                                          
                                          No IORT-50\                                                                                                                                                                                                       
                                          Recurrent-25%, GTR-75%                                                                                                                                                                                            

  Ballo *et al*. \[[@ref94]\] 2007        83\                       Retrospective cohort         IOERT       10--15           100      47                 \                                                NR                                               NR
                                          IORT-18\                                                                                                        IORT-46\                                                                                          
                                          No IORT-63\                                                                                                     No IORT-51\                                                                                       
                                          Recurrent-28%, *R*+-47%                                                                                         *p* = 0.9                                                                                         

  Dziewirski *et al*. \[[@ref95]\] 2010   57\                       Prospective cohort           HDR-IORT    20               60       20                 51                                               55                                               NR
                                          Recurrent -74%, GTR-85%                                                                                                                                                                                           

  Sweeting *et al*. \[[@ref96]\] 2013     18\                       Retrospective cohort         IOERT       10--20           94       43                 64                                               72                                               NR
                                          Recurrent-28%, GTR-100%                                                                                                                                                                                           

  Roeder *et al*. \[[@ref97]\] 2014       27\                       Prospective cohort           IOERT       10--20           100      33                 72                                               74                                               Total-6% late toxicity
                                          Recurrent-15%, GTR-100%                                                                                                                                                                                           

  Stucky *et al*. \[[@ref98]\] 2014       63\                       Retrospective cohort         IOERT       10--20           \        45                 \                                                \                                                Ureteral stricture-1\
                                          IORT-37\                                                                            100\                        IORT-89\                                         IORT-60\                                         No grade-3 neuropathy
                                          Sx only-26\                                                                         0                           Sx-46\                                           No IORT-60                                       
                                          Recurrent-36%,GTR-89%                                                                                           *p* = 0.03                                                                                        

  Gronchi *et al*. \[[@ref99]\] 2014      83\                       Prospective cohort           IOERT       10--12           88       58                 63                                               59                                               NR
                                          IORT-14pts only\                                                                                                                                                                                                  
                                          Recurrent-24%\                                                                                                                                                                                                    
                                          GTR-84%                                                                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomised control trial, PORT: post-operative RT, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,

Number of patients

In GTR patients,

α-crude rate

###### Studies of IORT in various paediatric tumours.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                          Sample size          Study design              IORT type   IORT dose (Gy)   EBRT %   Median Follow-up   LC 5 year (%)   OS 5 year (%)   Toxicity grade 3 or \>
  ------------------------------------ -------------------- ------------------------- ----------- ---------------- -------- ------------------ --------------- --------------- ---------------------------------------------------------
  Haase *et al* \[[@ref102]\] 1994     25 (neuroblastoma)   Prospective, single arm   IOERT       10--17           NR       51 (mean)          75              63              No late effects at 5-year follow-up

  Nag *et al* \[[@ref106]\] 2003       13 (5 metastatic)    Retrospective             IOERT       10--15           38       42                 72\             31\             late morbidity-30%
                                                                                                                                               (3yr)           (3yr)           

  Goodman *et al* \[[@ref104]\] 2003   66 (35% recurrent)   Retrospective             HDR-IORT    12--15           44       12                 56\             54\             Late morbidity-12%
                                                                                                                                               (2yr)           (2yr)           

  Oertel *et al*\                      18 (17% recurrent)   Retrospective             IOERT       8--15            100      54.5               95\             83\             late morbidity-33%\
  \[[@ref103]\] 2005                                                                                                                           (3yr)           (3yr)           Loss of Limb-1[^\*^](#table7-fn1){ref-type="table-fn"}\
                                                                                                                                                                               Neuropathy-1[^\*^](#table7-fn1){ref-type="table-fn"}

  Stauder *et al* \[[@ref107]\] 2011   20                   Retrospective             IOERT       7.5--25          100      139                77\             65\             No grade 3 or more late effects or second primary
                                                                                                                                               (10yr)          (10yr)          

  Sole *et al* \[[@ref105]\] 2015      71 (35% recurrent)   Retrospective             IOERT       7.5--20          100      72                 68\             74\             Late morbidity-13%\
                                                                                                                                               (10yr)          (10yr)          Neuropathy-4[^\*^](#table7-fn1){ref-type="table-fn"}\
                                                                                                                                                                               Necrosis-2[^\*^](#table7-fn1){ref-type="table-fn"}\
                                                                                                                                                                               Lymphedema-2[^\*^](#table7-fn1){ref-type="table-fn"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,

Number of patients.

###### Studies of IORT in recurrent gynaecological malignancies after gross total resection.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                                      Sample size   Site                               Primary/Recurrent   IORT type        IORT dose (Gy)   Prior EBRT %   Present EBRT %   Median follow-up   LC 5yr (%)        OS 5yr (%)            Toxicity grade 3 or \>
  ------------------------------------------------ ------------- ---------------------------------- ------------------- ---------------- ---------------- -------------- ---------------- ------------------ ----------------- --------------------- ----------------------------------------------------------------
  Haddock *et al*. \[[@ref113], [@ref115]\] 1996   63            Cervix-40\                         Primary-16%\        IOERT            8--25            0\             100\             NR                 61                27                    Total-17%\
                                                                 Endometrium-16\                    Recurrent-84%                                         70             63                                                                          GI-5[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Others-8                                                                                                                                                                            Neuropathy-2[^\*^](#table8-fn1){ref-type="table-fn"}

  Mahe *et al*. \[[@ref124], [@ref125]\] 1996      70            Cervix                             Recurrent-100%      IOERT\           10--30           97             42               15                 21 (3yr)          8 (3yr)               Total-14%Neuropathy-5[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                        X ray IORT                                                                                                                   Ureteral obstruction-4[^\*^](#table8-fn1){ref-type="table-fn"}

  Del carmen *et al*. \[[@ref126]\] 2000           15            Cervix-5Endometrium-3\             Recurrent-93%       IOERT            10--22.5         60             6                NR                 NR                74                    Neuropathy-4[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Vagina-7                                                                                                                                                                            GU-3[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                     Lymphedema-2[^\*^](#table8-fn1){ref-type="table-fn"}

  Martinez-monge *et al*.\[[@ref116]\] 2001        67            Cervix                             Primary-46%\        IOERT            10--25\          \              97\              58\                80.5\             58 (10yr)\            Total-14.9%\
                                                                                                    Recurrent-54%                        10--20           86             14               19                 49                14 (10yr)             Neuropathy-1[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                     Chronic pain-8[^\*^](#table8-fn1){ref-type="table-fn"}

  Gemignani *et al*. \[[@ref114]\] 2001            17            Cervix-9\                          Recurrent-\         HDR-IORT         12--15           82             12               20                 67 (3yr)          54 (3yr)              GI-4[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Endometrium-7\                     100%                                                                                                                                             Neuropathy-3[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Vagina-1                                                                                                                                                                            Wound-4[^\*^](#table8-fn1){ref-type="table-fn"}

  Dowdy *et al*. \[[@ref126]\] 2006                25            Endometrium                        Recurrent-\         IOERT            10--25           56             84               34                 84                *R*0-71\              Neuropathy-8[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                    100%                                                                                                                       *R*1-47\              GU-5[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                               *R*2-0                Fitula-5[^\*^](#table8-fn1){ref-type="table-fn"}

  Tran *et al*. \[[@ref118]\]\                     36            Cervix-17\                         Recurrent-89%       X-ray IORT       6--17.5          72             53               50                 44                47                    Total-27%\
  2007                                                           Endometrium-11\                                                                                                                                                                     Wound-4[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Others-8                                                                                                                                                                            GI-1[^\*^](#table8-fn1){ref-type="table-fn"}

  Barney *et al* \[[@ref119]\].2013                86            Cervix-100                         Recurrent-85%       IOERT            6--25            81             71               32                 Primary-70\       25\                   GI-4[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                             Recurrent-61%\    (3yr)                 GU-4[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                             (3yr)                                   Neuropathy-1[^\*^](#table8-fn1){ref-type="table-fn"}

  Calvo *et al*.\[[@ref120]\] 2013                 35            Cervix-20 Endometrium-7 Others-8   Recurrent-\         IOERT            10--15           71             46               46                 58                42                    Fistula-5[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                    100%                                                                                                                                             Ureter stenosi-2[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                     Neuropathy-1[^\*^](#table8-fn1){ref-type="table-fn"}

  Backes *et al*.\[[@ref127]\] 2014                32            Cervix-21\                         Recurrent-\         IOERT/HDR-IORT   10--20           100            0                NR                 PE+IORT-10Mon\    PE+IORT-10Mon\        NR
                                                                 Others-11\                         100%                                                                                                     LEER+IORT-9Mon\   LEER+IORT-10Mon\      
                                                                 IORT in 66% only                                                                                                                            PE-33Mon          PE-41Mon              

  Foley *et al*.\[[@ref121]\] 2014                 32            Cervix-21\                         Rccurent-81%        IOERT            10--22.5         88             20               26                 *R*1-73\          *R*1-77\              Total-47%\
                                                                 Endometrium-6\                                                                                                                              *R*2-71           *R*2-55 *p* = 0.001   GU-2\
                                                                 Others-5                                                                                                                                                                            Lymphedema-2

  Sole *et al*. \[[@ref117]\] 2014                 61            Cervix-18\                         Recurrent\          IOERT            10--15           66             48               42                 65                45                    Total-20%\
                                                                 Endometrium-32\                    Pelvic-57%\                                                                                                                                      Fistula-5[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Ovarian-9\                         Para-aortic-\                                                                                                                                    Neuropathy-1[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Vagina-2                           43%                                                                                                                                              Wound-3[^\*^](#table8-fn1){ref-type="table-fn"}

  Arians *et al*.\[[@ref122]\] 2016                36            Cervix-18\                         Recurrent-\         IOERT            10--18           76\            11\              14                 Cervix-0\         Cervix-6\             Wound complications-5[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Endometrium-12\                    100%                                                  25\            17\                                 Endometrium-40\   Endometrium-50\       Neuropathy-4[^\*^](#table8-fn1){ref-type="table-fn"}\
                                                                 Vulva-6                                                                                  100            17                                  Vulva-20\         Vulva-17\             Lymphedema-3[^\*^](#table8-fn1){ref-type="table-fn"}
                                                                                                                                                                                                             *p* = 0.017       *P* = 0.038           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sx: surgery, LC: local control, OS: overall survival, NR: not reported,

Number of patients

PE: pelvic exenteration, LEER: laterally extended endopelvic resection, Mon: median survival in months.

###### Studies of IORT in bladder and renal cancers.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                              Sample size             Study design           IORT type   IORT dose (Gy)   Prior EBRT %   Present EBRT %   Median follow-up months   LC 5 year %    OS 5 year %         Toxicity grade 3 or \>
  ---------------------------------------- ----------------------- ---------------------- ----------- ---------------- -------------- ---------------- ------------------------- -------------- ------------------- -----------------------------------------------------------------------------------------------------------------
  Hallemeier *et al*. \[[@ref128]\] 2013   Bladder-13, Ureter-4\   Retrospective cohort   IOERT       10--20           24             94               43.2\                     51\            16 (5 yr)\          Total-12%\
                                           Recurrent-88%                                                                                               In survivors              (2 yr)         *R*0+*R*1: 56\      Ureter stricture-4\
                                                                                                                                                                                                *R*2-11\            Fistula-1
                                                                                                                                                                                                *p* = 0.03 (2 yr)   

  Paly *et al*. \[[@ref134]\] 2014         98-RCC\                 Retrospective          IOERT       9.5--20          --             63               42\                       76             Advanced-37\        Total-5%\
                                           Recurrent-72%                                                                                               In survivors                             Recurrent-55        Pancreatic leak-3[^\*^](#table9-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                    gastritis-1[^\*^](#table9-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                    ARDS-1[^\*^](#table9-fn1){ref-type="table-fn"}

  Calvo *et al*. \[[@ref130]\] 2013        25-RCC\                 Retrospective          IOERT       9--15            \-             60               266                       80             38                  Total-24%
                                           Recurrent-40%                                                                                                                                                            

  Habl *et al*. \[[@ref132]\] 2013         17-RCC\                 Retrospective          IOERT       10--20           --             65               18                        91 (2 yr)      73\                 None
                                           Recurrent-100%                                                                                                                                       (2 yr)              

  Hallemeier *et al*. \[[@ref129]\] 2012   22-RCC\                 Retrospective          IOERT       10--20           \-             95               119\                      73             40\                 Total-23%\
                                           Recurrent-86%                                                                                               In survivors                             *R*0-80\            ARDS-1[^\*^](#table9-fn1){ref-type="table-fn"} Pancreatic pseudocyst-1[^\*^](#table9-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                *R*1-29\            Perforated ulcer-2[^\*^](#table9-fn1){ref-type="table-fn"}
                                                                                                                                                                                                *p* = 0.057         

  Master *et al*. \[[@ref133]\] 2005       14-RCC\                 Retrospective          IOERT       12--20           --             NR               66\                       85\            30                  NR
                                           Recurrent-100%                                                                                              (mean in survivors)       (crude rate)                       

  Eble *et al*. \[[@ref131]\] 1998         11-RCC\                 Retrospective          IOERT       15--20           \-             100              24                        100            47\                 Wound-2[^\*^](#table9-fn1){ref-type="table-fn"}\
                                           Recurrent-73%                                                                                                                                        (4 yr)              None IORT related
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomised control trial, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR:-not reported,

Number of patients

ARDS: acute respiratory distress syndrome.

###### IORT studies for prostate cancers.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                            Sample size                                            Study design            IORT type   IORT dose (Gy)   Present EBRT %          Median follow-up months   LC 5 year %    OS 5 year %   Toxicity grade 3 or \>
  -------------------------------------- ------------------------------------------------------ ----------------------- ----------- ---------------- ----------------------- ------------------------- -------------- ------------- ------------------------------------
  Krengli *et al*. \[[@ref139]\] 2010    38 (intermediate--\                                    Prospective             IOERT       10--12           Margin +ve and/or ECE   18.2                      NR             NR\           No grade 3\
                                         high-risk Pca,\                                                                                                                                                                            complications
                                         Margin +ve: 71%)                                                                                                                                                                           

  Rocco *et al*. \[[@ref136]\] 2009      IORT-33\                                               Matched pair analysis   IOERT       12               IORT-88\                16                        IORT-97\       100\          Acute grade ≥ 2\
                                         (intermediate--\                                                                                            *R*1, pT4, N+\                                    RP-86 (bRFS)   ( 2yr)        IORT vs. RP\
                                         high-risk Pca,\                                                                                             RP-44                                                                          GU-7% vs. 5%\
                                         Margin +ve: 24%)\                                                                                                                                                                          GI-3% vs. 4%\
                                         RP-100                                                                                                                                                                                     Lategrade ≥ 2\
                                                                                                                                                                                                                                    IORT vs. RP\
                                                                                                                                                                                                                                    GU-3% vs. 1%\
                                                                                                                                                                                                                                    GI-0% vs. 1%

  Saracino *et al* \[[@ref141]\] 2007    34\                                                    Prospective             IOERT       16--22           None                    41                        77.3\          71\           None
                                         (intermediate-risk Pca, Margin +ve: 41%)                                                                                                                      (3-yr bRFS)    (3-yr)        

  Orrechia *et al*. \[[@ref140]\] 2007   11\                                                    Prospective             IOERT       12               67                      NR                        NR             NR            1 had acute symptomatic lymphocele
                                         (high-risk Pca)                                                                                                                                                                            

  Kato *et al*. \[[@ref138]\] 1998       54\                                                    Prospective             IOERT       25--30           100\                    54                        83 (LC)\       NR            Late rectal toxicity-7%\
                                         Stage B2-D1[^α^](#table10-fn1){ref-type="table-fn"}\                                                        (30 Gy)                                           75\                          (No toxicity with IORT of 25 Gy)
                                         No RP                                                                                                                                                         (bRFS)                       

  Higashi *et al*. \[[@ref137]\] 1998    35\                                                    Prospective             IOERT       25--30           100\                    NR                        NR             Stage B-92\   NR
                                         Stage B-C[^α^](#table10-fn1){ref-type="table-fn"}\                                                          (30 Gy)                                                          Stage C-87    
                                         No RP                                                                                                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomised control trial, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported, \*Number of patients, RP: radical prostatectomy, Pca: prostate cancer, ECE: extra capsular extension, *R*1: margin +ve, *N*+: node-positive disease, bRFS: biochemical relapse-free survival,

Whitmore-Jewett staging system \[Whitmore 1956, Jewett 1975\].

###### IORT studies for gastric cancers.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                            Sample size                                 Study design           IORT type   IORT dose (Gy)   EBRT (%)                                                       Type of nodal dissection   Median follow-up (months)   LRC                 OS 5 year (%)                        Toxicity grade 3 or \>
  -------------------------------------- ------------------------------------------- ---------------------- ----------- ---------------- -------------------------------------------------------------- -------------------------- --------------------------- ------------------- ------------------------------------ -----------------------------------------------------------
  Sindelar *et al*. \[[@ref149]\] 1993   Sx+IORT-27\                                 RCT                    IOERT       20               0\                                                             NR                         84                          37\                 25 months (M.S)\                     Fistula:\
                                         Sx+/-EBRT-33                                                                                    72                                                                                                                    8\                  21 months (M.S)\                     IORT-4 vs. Sx-5[^\*^](#table11-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                               *p* \< 0.001        *p* = 0.99                           Enteritis:\
                                                                                                                                                                                                                                                                                                                        IORT-0 vs. Sx-2[^\*^](#table11-fn1){ref-type="table-fn"}

  Abe *et al* \[[@ref1]\] 1995           IORT-94\                                    NRC                    IOERT       28--35           none                                                           NR                         NR                          NR                  Stage II:\                           NR
                                         No IORT-127                                                                                                                                                                                                                               IORT-78\                             
                                                                                                                                                                                                                                                                                   No IORT-66\                          
                                                                                                                                                                                                                                                                                   Stage III:\                          
                                                                                                                                                                                                                                                                                   IORT-60\                             
                                                                                                                                                                                                                                                                                   No IORT-51\                          
                                                                                                                                                                                                                                                                                   Stage IV:\                           
                                                                                                                                                                                                                                                                                   IORT-33\                             
                                                                                                                                                                                                                                                                                   No IORT-14 (all N.S)                 

  Avizonis *et al*.\[[@ref158]\] 1995    27                                          Prospective phase II   IOERT       12.5--16.5       79                                                             NR                         NR                          85                  47\                                  Acute\
                                                                                                                                                                                                                                                                                   (2yr)                                toxicity-14%\
                                                                                                                                                                                                                                                                                                                        Late-7%

  Ogata *et al*. \[[@ref152]\] 1995      IORT-58\                                    Retrospective          IOERT       12               None                                                           D2                         NR                          NR                  Stage II:\                           None
                                         No IORT-120                                                                                                                                                                                                                               IORT-100,\                           
                                                                                                                                                                                                                                                                                   No IORT-63 (4yr)\                    
                                                                                                                                                                                                                                                                                   Stage III:\                          
                                                                                                                                                                                                                                                                                   IORT-55\                             
                                                                                                                                                                                                                                                                                   No IORT-35 (8yr)\                    
                                                                                                                                                                                                                                                                                   Stage IV:\                           
                                                                                                                                                                                                                                                                                   IORT-12\                             
                                                                                                                                                                                                                                                                                   No IORT-13 (5yr)                     

  Coquard *et al*. \[[@ref156]\] 1997    63\                                         Retrospective          IOERT       12--23           48                                                             D1-89%                     61 in survivors             76 (crude rate)     47                                   None attributed to IORT
                                         (*R*0-92%)                                                                                                                                                                                                                                                                     

  Skoropad *et al*. \[[@ref154]\] 2000   78\                                         RCT                    IOERT       20               100\                                                           D1                         NR                          NR                  Entire cohort:\                      Similar acute toxicity in both arms\
                                         Pre-op RT+IORT+ Sx vs. Sx alone                                                                 (Pre-op RT-20 Gy/5[^\#^](#table11-fn2){ref-type="table-fn"})                                                                              IORT:21months\                       Higher pancreatitis surgery alone.\
                                                                                                                                                                                                                                                                                   No IORT: 9months\                    No RT late toxicity
                                                                                                                                                                                                                                                                                   (*P* = 0.311)\                       
                                                                                                                                                                                                                                                                                   Node +ve and\                        
                                                                                                                                                                                                                                                                                   Advanced stage: IORT vs. No IORT:\   
                                                                                                                                                                                                                                                                                   *p* \< 0.05                          

  Weese *et al*. \[[@ref159]\] 2000      16\                                         Prospective            IOERT       10               88                                                             D2                         27                          93 (crude rate)     66 (crude rate at 3yr)               NR
                                         (IORT-56%)                                                                                                                                                                                                                                                                     

  Glehen *et al*. \[[@ref160]\] 2003     42\                                         Retrospective          IOERT       12--15           97                                                             NR                         131                         79                  45                                   NR
                                         (All Node +ve, *R*0-93%)                                                                                                                                                                                                                                                       

  Miller *et al*. \[[@ref161]\] 2006     50\                                         Retrospective          IOERT       10--25           96                                                             NR                         19                          75                  15 (5 yr)                            Acute-48%\
                                         (*R*0-42%, recurrent-26%, oesophagus-14%)                                                                                                                                                                                                                                      Chronic-26%\
                                                                                                                                                                                                                                                                                                                        GI-6[^\*^](#table11-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                        Overall treatment-related mortality-6%

  Qin *et al*. \[[@ref153]\] 2006        IORT-106\                                   NRC                    IOERT       10--30           None                                                           D2/3                       NR                          NR                  Stage III D2:\                       NR
                                         No IORT-441                                                                                                                                                                                                                               IORT- 60%\                           
                                                                                                                                                                                                                                                                                   No IORT-36%\                         
                                                                                                                                                                                                                                                                                   *p* \< 0.005\                        
                                                                                                                                                                                                                                                                                   Stage III D3:\                       
                                                                                                                                                                                                                                                                                   IORT-61%\                            
                                                                                                                                                                                                                                                                                   No IORT-56%\                         
                                                                                                                                                                                                                                                                                   *p* \> 0.05                          

  Drognitz *et al*. \[[@ref151]\] 2007   IORT-61\                                    NRC                    IOERT       15--25           None                                                           D2                         56                          90                  IORT-58%\                            Perioperative mortality-4.9% both groups\
                                         No IORT-61\                                                                                                                                                                                                                               No IORT-59%\                         Surgical morbidity:\
                                         (*R*0-100%)                                                                                                                                                                                                                               *p* = 0.99                           IORT:44%\
                                                                                                                                                                                                                                                                                                                        No IORT: 20%

  Fu *et al*. \[[@ref148]\] 2008         97\                                         Prospective            IOERT       12--15           100%\                                                          D2                         24                          77\                 44\                                  Late toxicity-3[^\*^](#table11-fn1){ref-type="table-fn"}\
                                         IORT-46\                                                                                        CTRT                                                                                                                  IORT- 77\           IORT-56\                             No difference among groups
                                         No IORT-51\                                                                                                                                                                                                           No IORT- 63\        No IORT-47\                          
                                         (*R*0-90%)                                                                                                                                                                                                            *p* = 0.05, (3Yr)   *p* = 0.20, (3Yr)                    

  Zhang *et al*. \[[@ref150]\] 2012      97\                                         Prospective            IOERT       12--15           100% CTRT                                                      D2                         37                          50\                 26\                                  IORT vs. No IORT\
                                         IORT-46\                                                                                                                                                                                                              IORT-50\            IORT-28\                             Acute-39% vs. 37%\
                                         No IORT-51\                                                                                                                                                                                                           No IORT-35\         No IORT-26\                          Late-.10% vs. 0%, *p* = 0.02\
                                         (*R*0-90%)                                                                                                                                                                                                            *p* = 0.04          *p* = 0.4                            Enteritis-1[^\*^](#table11-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                        Haemorrhage-4[^\*^](#table11-fn1){ref-type="table-fn"}

  Calvo *et al*. \[[@ref155]\] 2012      32\                                         Retrospective          IOERT       10--15           47                                                             D2                         40                          84                  55                                   Acute GI-5[^\*^](#table11-fn1){ref-type="table-fn"}
                                         (*R*0-100%)                                                                                                                                                                                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomised control trial, NRC: non-randomised comparison, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,

Number of patients,

fractions,

Pre-op: pre-operative, M.S: median survival, N.S: non-significant.

###### Studies of IORT in the management of pancreatic cancers.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/Year                             Sample size                           Study design             IORT type   IORT dose (Gy)   EBRT %                 Median follow-up   LC 5 year (%)                              OS 5 year (%)                                            Toxicity grade 3 or \>
  --------------------------------------- ------------------------------------- ------------------------ ----------- ---------------- ---------------------- ------------------ ------------------------------------------ -------------------------------------------------------- -------------------------------------------------------------------
  Mohiuddin *et al*. \[[@ref178]\] 1995   49 UR-PC\                             Retrospective            IOERT       10--20           100\                   28                 69                                         7 (4yr)                                                  Acute toxicity-14%\
                                          (Resected-0%)                                                                               (Post-op)                                                                                                                                     GI bleeding-2[^\*^](#table12-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                    Late toxicity-19%\
                                                                                                                                                                                                                                                                                    GI bleeding-3[^\*^](#table12-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                    Obstruction-2[^\*^](#table12-fn1){ref-type="table-fn"}

  Nishimura *et al*. \[[@ref179]\] 1997   Resected-157\                         Retrospective            IOERT       12--33 Gy        Resected-\             NR                 NR                                         Resected:\                                               IORT:\
                                          IORT- 55\                                                                                   70\                                                                                  IORT-16\                                                 Late toxicity:\
                                          No IORT-102\                                                                                Unresectable-87\                                                                     No IORT-0 (2yr)\                                         gastric ulcer-18[^\*^](#table12-fn1){ref-type="table-fn"}\
                                          Unresectable-175\                                                                           (Pre-op or post-op)                                                                  Unresectable:\                                           Intestinal perforation-4[^\*^](#table12-fn1){ref-type="table-fn"}
                                          IORT-71\                                                                                                                                                                         IORT-14\                                                 
                                          No IORT-104                                                                                                                                                                      No IORT-0\                                               
                                                                                                                                                                                                                           *p* \< 0.05 (2yr)                                        

  Ma *et al*. \[[@ref177]\] 2004          81 UR-PC\                             Retrospective            IOERT       15--25           80\                    NR                 NR\                                        \                                                        IORT vs IORT+EBRT:\
                                          (Resected-0%)\                                                                              (Post-op)                                 (60% complete pain relief with IORT)       10.7 (M.S)\                                              Delayed gastric\
                                          IORT-18\                                                                                                                                                                         12.2 (M.S)\                                              emptying: 3 vs 2[^\*^](#table12-fn1){ref-type="table-fn"}
                                          IORT+EBRT-25\                                                                                                                                                                    5.1 (M.S)\                                               
                                          EBRT-16\                                                                                                                                                                         7 (M.S)                                                  
                                          Palliative Sx-22                                                                                                                                                                                                                          

  Willet *et al*. \[[@ref180]\] 2005      150 UR-PC\                            Retrospective            IOERT       15--20 Gy        100 (Pre/post-op RT)   NR                 NR                                         7 (3Yr)                                                  Post-operative complications- 20%\
                                          (Resected-0%)\                                                                                                                                                                                                                            Late toxicity- 15%\
                                                                                                                                                                                                                                                                                    Upper GI bleed-16[^\*^](#table12-fn1){ref-type="table-fn"}

  Jingu *et al*. \[[@ref176]\] 2012       322\                                  Retrospective            IOERT       20--30           29 (post-op RT)        38                 64                                         9\                                                       Late toxicity\
                                          Resected-83\                                                                                                                                                                     *R*2:HR-2.03,\                                           GI-4[^\*^](#table12-fn1){ref-type="table-fn"}
                                          Unresectable- 109\                                                                                                                                                               *p* \< 0.001                                             
                                          Metastatic-130 (exclude)                                                                                                                                                                                                                  

  Cai *et al*. \[[@ref174]\] 2013         194 UR-PC\                            Retrospective            IOERT       10--25           97% (Pre-op CTRT)      12                 38 (3yr)                                   6 (3yr)                                                  Acute toxicity- 21%\
                                          (Resected-0%)                                                                                                                                                                                                                             Late toxicity-14%\
                                                                                                                                                                                                                                                                                    Haemorrhage-23[^\*^](#table12-fn1){ref-type="table-fn"}

  Chen *et al*. \[[@ref175]\]\            247 UR-PC\                            Retrospective            IOERT       10--20           51% (Post-op CTRT)     10                 35 (3yr)\                                  7.2 (3yr)                                                Post-operative complications-14%\
  2016                                    (Resected-0%)                                                                                                                         Complete pain relief-70%                                                                            Fistula-11[^\*^](#table12-fn1){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                    Haemorrhage- 7[^\*^](#table12-fn1){ref-type="table-fn"}

  Keane *et al*. \[[@ref181]\] 2016\      68 UR-PC\                             Retrospective            IOERT       \                100 % (NACTRT)         21                 NR                                         \                                                        No significant difference in post-operative complications
                                          After NACTRT\                                                              8--13\                                                                                                35.1 (M.S)\                                              
                                          Resected-41 IORT-22 (R1-73%)\                                              15--17                                                                                                24.5 (M.S)\                                              
                                          No IORT-19\                                                                                                                                                                      24.8 (M.S)                                               
                                          Unresectable-18 (IORT-17)                                                                                                                                                                                                                 

  Kokubo *et al*. \[[@ref172]\] 2000      138 R/BR-PC\                          Retrospective            IOERT       20--30           45\                    NR                 NR                                         *R*0:19\                                                 Acute toxicity- none\
                                          (Resected-100%, *R*1-29%)                                                                   (Pre-op:13%\                                                                         *R*1:4\                                                  Late toxicity-\
                                                                                                                                      Post op-47%\                                                                         *p* \< 0.005\                                            GI ulcers-20%\
                                                                                                                                      Both-40%)                                                                            (2-yr cause specific survival)                           Perforation-2[^\*^](#table12-fn1){ref-type="table-fn"}

  Alfieri *et al*. \[[@ref165]\] 2001     46 R/BR-PC (Resected-100%)\           NRC                      IOERT       10               \                      82                 \                                          \                                                        IORT vs. No IORT\
                                          IORT-26 (R1-10%)\                                                                           100\                                      IORT-58\                                   IORT-16\                                                 Acute morbidity-\
                                          No IORT-20 (R1-13%)                                                                         0\                                        No IORT-30\                                No IORT-6\                                               57% vs. 43% (*p* = 0.1)\
                                                                                                                                      (Post-op)                                 *p* \< 0.001                               *p* = 0.06                                               Perioperative mortality-\
                                                                                                                                                                                                                                                                                    8% vs. 9%

  Reni *et al*. \[[@ref173]\] 2001        127 R/BR-PC\                          Retrospective            IOERT       10--25           \                      21 (in\            Stage I-II:\                               Stage I--II:\                                            IORT vs. No IORT: Acute toxicity: N.S difference\
                                          (Resected-82%)\                                                                             32\                    survivors)         IORT-73\                                   IORT-22\                                                 Chronic toxicity:\
                                          IORT- 127\                                                                                  20\                                       No IORT-40\                                No IORT-6\                                               Abdominal pain 15 vs. 22%\
                                          (*R*0-1:104, *R*2-23)\                                                                      (Post-op)                                 Stage III-IVA:\                            Stage III-IVA:\                                          Late GI bleed-6 vs. 3%\
                                          No IORT- 76 (*R*0-1:62, *R*2-14)                                                                                                      IORT-50\                                   IORT-3\                                                  Stenosis-3% vs. 0%
                                                                                                                                                                                No IORT-45                                 No IORT-5                                                

  Messick *et al*. \[[@ref169]\] 2008     49 R/BR-PC (Resected-100%, R1-74%)\   NRC                      IOERT       10--12           \                      \                  \                                          \                                                        IORT vs. No IORT: Delayed gastric emptying-6.7 vs. 4.2%\
                                          IORT-22\                                                                                    76\                    10.1\              IORT-82\                                   IORT-20 (M.S)\                                           Wound infection-4.5 vs. 22%\
                                          No IORT-27\                                                                                 64                     13.3               No IORT-88\                                No IORT-13 (M.S)\                                        Pancreatic fistula 10 vs. 4.8% (N.S)
                                                                                                                                                                                (N.S)                                      (N.S)                                                    

  Valentini *et al*. \[[@ref171]\] 2008   26 R/BR-PC\                           Retrospective            IOERT       10               100\                   102 in survivors   57                                         15                                                       Perioperative\
                                          Resected-100%, *R*1-4%\                                                                     (Post-op: 65%)                                                                                                                                complications-11%

  Showalter *et al*. \[[@ref167]\] 2009   R/BR-PC\                              Retrospective            IOERT       10--20           74\                    NR                 IORT-79\                                   IORT-21 (M.S)\                                           Perioperative\
                                          IORT-37 (*R*1-2:43%)\                                                                       66\                                       No IORT-61\                                No IORT-19 (M.S)                                         complications-46% vs. 40% (N.S)
                                          No IORT-46 (*R*1-2: 30%)                                                                    (Post-op RT)                              *p* = 0.19                                                                                          

  Valentini *et al*. \[[@ref168]\] 2009   270\                                  ISIORT Pooled analysis   IOERT       7.5--25          64\                    96                 23\                                        18\                                                      Acute toxicity- None \> G2\
                                          Resected-81%\                                                                               (pre-op:24\                               Pre-op RT vs. post-op RT vs. IORT alone\   IORT + Pre-op RT vs. IORT + post-op RT vs. IORT alone\   Late-NS
                                          (*R*1-27%)                                                                                  Post-op:40)                               *p* \< 0.0001                              *p* \< 0.0001                                            

  Ogawa *et al*. \[[@ref170]\] 2010       210 R/BR-PC\                          Retrospective            IOERT       20--30           30                     26                 84 (2yr)                                   42 (2yr)                                                 Late toxicity\
                                          Resected-100%, R1-32%                                                                                                                                                                                                                     GI-7[^\*^](#table12-fn1){ref-type="table-fn"}

  Calvo *et al*. \[[@ref166]\]\           60 R/BR-PC\                           Prospective              IOERT       10--15           100%\                  16                 58\                                        20\                                                      Perioperative complications-43% (N.S)\
  2013                                    (Resected-83%,\                                                                             (Pre-op CTRT-32%)                         No IORT:\                                                                                           Chronic-17%\
                                          *R*1-43%)\                                                                                                                            HR-6.75,\                                                                                           Neuropathy-4[^\*^](#table12-fn1){ref-type="table-fn"}\
                                          IORT-29\                                                                                                                              *p* = 0.01                                                                                          GI-3[^\*^](#table12-fn1){ref-type="table-fn"}
                                          No IORT-31                                                                                                                                                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomised control trial, NRC: non-randomised comparison, Sx: surgery, LC: local control, OS: overall survival, DFS: disease-free survival, NR: not reported,

Number of patients,

^\#^ fractions, Pre-op: pre-operative, Post-op: post-operative, M.S: median survival in months, N.S: non-significant, R/BR-PC: resectable/borderline resectable pancreatic cancer, UR-PC: unresectable pancreatic cancer, NACTRT: neoadjuvant chemoradiotherapy, Resected: complete resections (R0/R1), Unresectable: R2/palliative resections.
